[go: up one dir, main page]

AR019308A1 - Formulaciones de particulas novedosas. - Google Patents

Formulaciones de particulas novedosas.

Info

Publication number
AR019308A1
AR019308A1 ARP990102392A ARP990102392A AR019308A1 AR 019308 A1 AR019308 A1 AR 019308A1 AR P990102392 A ARP990102392 A AR P990102392A AR P990102392 A ARP990102392 A AR P990102392A AR 019308 A1 AR019308 A1 AR 019308A1
Authority
AR
Argentina
Prior art keywords
formulations
novelties
new
compounds
animals
Prior art date
Application number
ARP990102392A
Other languages
English (en)
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of AR019308A1 publication Critical patent/AR019308A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invencion provee vehículos capaces de suministrar concentraciones elevadas de compuestos pobremente hidrofílicos/pobremente lipofílicos a animales,mediante la combinacion de compuestos que poseen dominios hidrofobicos biocompatibles con conjugados que poseen regiones tanto hidrofobicas como hidrofílicas.Dichas formulaciones son adecuadas para una cantidad de usos en animales, particularmente la administracion a los mismos de altas concentraciones de compuestosterapéuticamente utiles, sin unnivel indebido de efectos colaterales.
ARP990102392A 1998-05-20 1999-05-19 Formulaciones de particulas novedosas. AR019308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8610898P 1998-05-20 1998-05-20

Publications (1)

Publication Number Publication Date
AR019308A1 true AR019308A1 (es) 2002-02-13

Family

ID=22196324

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102392A AR019308A1 (es) 1998-05-20 1999-05-19 Formulaciones de particulas novedosas.

Country Status (18)

Country Link
US (1) US6500461B2 (es)
EP (1) EP1079812A4 (es)
JP (1) JP2002535242A (es)
KR (1) KR20010052368A (es)
CN (1) CN1310612A (es)
AR (1) AR019308A1 (es)
AU (1) AU745015B2 (es)
BR (1) BR9911031A (es)
CA (1) CA2332545A1 (es)
EA (1) EA200001109A1 (es)
EE (1) EE200000693A (es)
ID (1) ID28166A (es)
IL (1) IL139541A0 (es)
NO (1) NO20005832L (es)
PL (1) PL344327A1 (es)
SK (1) SK17422000A3 (es)
TR (1) TR200003435T2 (es)
WO (1) WO1999059550A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
CA2574767C (en) 2004-07-19 2015-02-17 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
JP2010534248A (ja) 2007-07-21 2010-11-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ピリジノン置換インダゾール
WO2009049083A1 (en) 2007-10-09 2009-04-16 Washington University In St. Louis Particles for imaging
WO2009049089A1 (en) 2007-10-09 2009-04-16 Washington University In St. Louis Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
EP2476680B1 (en) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinone)-Substituted Pyridoindoles
US9579400B2 (en) 2008-09-23 2017-02-28 The Regents Of The University Of California Nanocarriers for drug delivery
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US8673931B2 (en) 2009-01-26 2014-03-18 Abraham Fisher Bicyclic heterocyclic spiro compounds
CN101670095B (zh) * 2009-04-13 2012-05-23 北京大学 一种用于栓塞治疗的药物组合物及其制备方法
CA2767233A1 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
JP2013514999A (ja) 2009-12-17 2013-05-02 ワシントン・ユニバーシティ 抗血栓性ナノ粒子
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011130674A1 (en) 2010-04-15 2011-10-20 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
AU2011248449B2 (en) 2010-05-03 2016-09-15 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8895055B2 (en) 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
US12226529B2 (en) 2015-08-25 2025-02-18 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
EP3512569A4 (en) 2016-09-15 2020-09-23 The Regents of The University of California ENHANCED HYBRID TELODENDRIMERS
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
CN113330056A (zh) 2018-08-31 2021-08-31 加利福尼亚大学董事会 基于花青的末端树枝状共聚物及其治疗癌症的用途
EP3906233B1 (en) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
JPH0429924A (ja) * 1990-05-28 1992-01-31 Terumo Corp 脂溶性薬物含有注射用製剤
CA2085342A1 (en) * 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
US5599556A (en) 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
JPH07509702A (ja) 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5776486A (en) * 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
WO1997010234A1 (en) * 1995-09-12 1997-03-20 The Liposome Company, Inc. Hydrolysis-promoting taxane hydrophobic derivatives
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same

Also Published As

Publication number Publication date
WO1999059550A1 (en) 1999-11-25
ID28166A (id) 2001-05-10
AU4190699A (en) 1999-12-06
US6500461B2 (en) 2002-12-31
EP1079812A1 (en) 2001-03-07
PL344327A1 (en) 2001-10-22
SK17422000A3 (sk) 2001-09-11
NO20005832D0 (no) 2000-11-17
TR200003435T2 (tr) 2001-03-21
KR20010052368A (ko) 2001-06-25
CN1310612A (zh) 2001-08-29
NO20005832L (no) 2001-01-18
EE200000693A (et) 2002-04-15
CA2332545A1 (en) 1999-11-25
JP2002535242A (ja) 2002-10-22
EA200001109A1 (ru) 2001-06-25
IL139541A0 (en) 2004-02-08
EP1079812A4 (en) 2001-12-12
BR9911031A (pt) 2002-01-29
AU745015B2 (en) 2002-03-07
US20020034536A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AR019308A1 (es) Formulaciones de particulas novedosas.
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
CY1109286T1 (el) Σκευασμα τυπου φυραματος που περιλαμβανουν διοξειδιο πυριτιου
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
AU7522601A (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
ES2052542T3 (es) Composiciones de hormonas del crecimiento, de liberacion sostenida, para administracion por via parenteral y su uso.
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
AR017779A1 (es) Formulaciones inyectables de larga actuacion y uso de la misma para la fabricacion de un preparado
PA8427301A1 (es) Preparado farmaceutico que contiene acidos difosfonicos para la aplicacion por via oral.
ES2195189T3 (es) Benzonaftiridinas como agentes terapeuticos bronquiales.
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
AR015360A1 (es) Proceso para la manufactura de una composicion farmaceutica para reducir o prevenir los efectos de la inflamacion; dicha composicion farmaceutica y unelemento para aplicar la composicion farmaceutica en dicho proceso
GT200100037A (es) Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina y que depende de la ciclina.
ATE482723T1 (de) Halbfeste mukoadhäsive formulierungen
AR032293A1 (es) Estuche farmaceutico
PT1140018E (pt) Suspensoes de poliol/oleo para a libertacao sustentada de proteinas
ES2194935T3 (es) Preparados estables de transglutaminasa y procedimiento para su preparacion.
CR7059A (es) USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS
ES2190082T3 (es) Concentrados estables de vitamina c.
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
HN1998000144A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa.
AR021750A1 (es) Aparato para el tratamiento topico localizado de una enfermedad